Merrimack Pharmaceuticals (MACK) Short Interest Ratio & Short Volume → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free MACK Stock Alerts $15.13 +0.01 (+0.07%) (As of 05/15/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Merrimack Pharmaceuticals Short Interest DataCurrent Short Volume842,500 sharesPrevious Short Volume815,900 sharesChange Vs. Previous Month+3.26%Dollar Volume Sold Short$12.42 millionShort Interest Ratio / Days to Cover5.9Last Record DateApril 30, 2024Outstanding Shares14,530,000 sharesPercentage of Shares Shorted5.80%Today's Trading Volume372,606 sharesAverage Trading Volume152,254 sharesToday's Volume Vs. Average245% Short Selling Merrimack Pharmaceuticals ? Sign up to receive the latest short interest report for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatMACK Short Interest Over TimeMACK Days to Cover Over TimeMACK Percentage of Float Shorted Over Time Ad InvestorPlaceElon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.Get all the information here. Merrimack Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2024842,500 shares $12.42 million +3.3%N/A5.9 $14.74 4/15/2024815,900 shares $11.98 million +12.9%N/A6.4 $14.68 3/31/2024722,800 shares $10.68 million -1.0%N/A6.2 $14.77 3/15/2024729,900 shares $10.76 million -5.7%N/A7 $14.74 2/29/2024774,100 shares $11.38 million -5.9%N/A8.4 $14.70 2/15/2024822,900 shares $12.10 million +7.9%N/A9.7 $14.70 Get the Latest News and Ratings for MACK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024763,000 shares $10.22 million +1.5%N/A16.8 $13.40 1/15/2024752,100 shares $9.91 million -3.8%N/A18.8 $13.17 12/31/2023781,400 shares $10.48 million -10.4%N/A20.1 $13.41 12/15/2023871,600 shares $11.54 million -3.6%N/A23.4 $13.24 11/30/2023904,300 shares $11.41 million -1.8%N/A26.4 $12.62 11/15/2023921,100 shares $11.76 million -0.5%N/A27 $12.77 10/31/2023926,100 shares $11.33 million -2.6%N/A27.2 $12.23 10/15/2023951,100 shares $11.67 million -3.5%N/A21.3 $12.27 9/30/2023985,100 shares $12.15 million -5.3%N/A19.1 $12.33 9/15/20231,040,000 shares $12.73 million -2.8%N/A10.5 $12.24 8/31/20231,070,000 shares $13.06 million -2.7%N/A10.2 $12.21 8/15/20231,100,000 shares $13.38 million +1.9%N/A10.2 $12.16 7/31/20231,080,000 shares $12.97 million +3.9%N/A9.4 $12.01 7/15/20231,040,000 shares $12.15 million +5.4%N/A9.5 $11.68 6/30/2023986,900 shares $12.14 million +38.3%N/A9.2 $12.30 6/15/2023713,500 shares $8.84 million +4.4%N/A7.4 $12.39 5/31/2023683,700 shares $8.56 million -5.1%N/A9.2 $12.52 5/15/2023720,200 shares $9.20 million -8.8%N/A9.5 $12.77 4/30/2023789,600 shares $9.80 million -12.7%6.0%9.8 $12.41 4/15/2023904,700 shares $11.62 million +6.7%6.9%9.9 $12.84 3/31/2023847,700 shares $10.42 million -5.2%6.5%7 $12.29 3/15/2023894,500 shares $10.33 million -4.7%6.9%6.2 $11.55 2/28/2023938,100 shares $10.77 million -2.7%7.7%6 $11.48 2/15/2023964,000 shares $11.24 million +3.6%7.4%5.9 $11.66 1/31/2023930,300 shares $10.78 million +11.1%7.1%1.2 $11.59 1/15/2023837,100 shares $10.13 million +4.1%6.4%1.1 $12.10 12/30/2022804,300 shares $9.22 million +60.9%7.2%1.1 $11.46 12/15/2022499,800 shares $5.77 million -23.1%4.5%0.7 $11.55 11/30/2022649,800 shares $7.74 million -23.1%5.8%1 $11.91 11/15/2022844,700 shares $10.39 million +226.0%7.5%1.3 $12.30 10/31/2022259,100 shares $976,807.00 +1.0%2.3%0.5 $3.77 10/15/2022256,600 shares $857,044.00 -0.8%2.3%7 $3.34 9/30/2022258,700 shares $970,125.00 +2.0%2.3%8 $3.75 9/15/2022253,700 shares $1.11 million -2.8%2.3%8.7 $4.38This is the best new way to score with AI (Ad)If you thought that you missed your chance to score big on AI, I have great news. A rare second profit window is starting to open.Click now for the best way into the newest AI projects MACK Short Interest - Frequently Asked Questions What is Merrimack Pharmaceuticals' current short interest? Short interest is the volume of Merrimack Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 842,500 shares of MACK short. Learn More on Merrimack Pharmaceuticals' current short interest. What is a good short interest ratio for Merrimack Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MACK shares currently have a short interest ratio of 6.0. Learn More on Merrimack Pharmaceuticals's short interest ratio. Is Merrimack Pharmaceuticals' short interest increasing or decreasing? Merrimack Pharmaceuticals saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 842,500 shares, an increase of 3.3% from the previous total of 815,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Merrimack Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Merrimack Pharmaceuticals: Emergent BioSolutions Inc. (14.13%), Rigel Pharmaceuticals, Inc. (3.23%), XOMA Co. (2.33%), Vanda Pharmaceuticals Inc. (4.17%), Regulus Therapeutics Inc. (7.33%), Verastem, Inc. (3.49%), Lexicon Pharmaceuticals, Inc. (9.52%), Veru Inc. (8.35%), Werewolf Therapeutics, Inc. (1.39%), Eliem Therapeutics, Inc. (0.31%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Merrimack Pharmaceuticals stock? Short selling MACK is an investing strategy that aims to generate trading profit from Merrimack Pharmaceuticals as its price is falling. MACK shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Merrimack Pharmaceuticals? A short squeeze for Merrimack Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of MACK, which in turn drives the price of the stock up even further. How often is Merrimack Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MACK, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Emergent BioSolutions Short Interest Rigel Pharmaceuticals Short Interest XOMA Short Interest Vanda Pharmaceuticals Short Interest Regulus Therapeutics Short Interest Verastem Short Interest Lexicon Pharmaceuticals Short Interest Veru Short Interest Werewolf Therapeutics Short Interest Eliem Therapeutics Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MACK) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 Media